H pylori drug cash claim

Drug treatment to eradicate Helicobacter pylori in infected patients with non-ulcer dyspepsia may be cost-effective, according to a new meta-analysis by the dyspepsia review group (BMJ, 16 September 2000, p659).

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of HSJ.co.uk and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here